Does extensive upper abdomen surgery during primary cytoreduction impact on long-term quality of life?

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 442-447

  Angioli, Roberto ^a   Plotti, Francesco ^a   Aloisi, Alessia ^a   Capriglione, Stella ^a   Terranova, Corrado ^a   Ricciardi, Roberto ^a   Montera, Roberto ^a   Zullo, Marzio Angelo ^a   Rasi, Virginia ^b   Benedetti Panici, Pierluigi ^c  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ovarian cancer; Quality of life; Upper abdomen

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ABDOMINAL SURGERY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SALPINGOOOPHORECTOMY;

ADULT; AGED; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84876226577     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182842fc4     Document Type: Article

References (30)

1. Lim MC, Kang S, Song YJ, et al. Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer. J Korean Med Sci. 2010;25:1034-1040.
2. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced ovarian epithelial carcinoma. Gynecol Oncol. 2001;82:532-537.
3. Winter WE 3rd, Maxwell GL, Tian C, et al. Gynecologic Oncology Group. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621-3627.
4. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma? Gynecol Oncol. 2006;103:559-564.
5. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248-1259.
6. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 2001;82:489-497.
7. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26-31.
8. Eisenkop SM, Friedman RL,Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69:103-108.
9. Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol. 2003;90:390-396.
10. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: A change in surgical approach. Gynecol Oncol. 2004;94:650-654.
11. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-1090.
12. Zivanovic O, Eisenhauer EL, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008;108:287-292.
13. Lee JH, Kim KS, Chung CW, et al. Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. J Korean Med Sci. 2002;17:415-418.
14. Bae J, Lim MC, Choi JH, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009;20:101-106.
15. Ang C, Chan KK, Bryant A, et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer [review]. Cochrane Database Syst Rev. 2011:CD007697.
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
17. Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100:455-461.
18. FIGO Cancer Committee. Staging announcement. Gynecol Oncol. 1986;25:383-385.
19. Dindo D, Dematrtines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and result of a survey. Ann Surg. 2004;240:205-213.
20. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment (Offset Publication No. 48). Geneva, Switzerland: World Health Organization; 1979:16-21.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the Response to Treatment in Solid Tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205-216.
22. Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33:2117-2123.
23. Greimel E, Bottomley A, Cull A, et al EORTC Quality of Life Group and the Quality of Life Unit. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402-1408. Published correction appears in Eur J Cancer. 2003;39(17):2570.
24. Cull A, Howat S, Greimel E, et al; EORTC Quality of Life Group [European Organization for Research and Treatment of Cancer]; Scottish Gynaecological Cancer Trials Group. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: A progress report. Eur J Cancer. 2001;37:47-53.
25. Scott NW, Fayers PM. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
26. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
27. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S161-S192.
28. Sugarbaker PH, Barofsky I, Rosenberg SA, et al. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery. 1982;91:17-23.
29. Blazeby JM, Avery K, Sprangers M, et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178-3186.
30. Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197-1203.